Connection
David Schwartz to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications David Schwartz has written about Antibodies, Monoclonal, Humanized.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.594 |
|
|
|
-
Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. Clin Gastroenterol Hepatol. 2022 05; 20(5):1059-1067.e9.
Score: 0.559
-
Pabla BS, Alex Wiles C, Slaughter JC, Scoville EA, Dalal RL, Beaulieu DB, Schwartz DA, Horst SN. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor a Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience. Dig Dis Sci. 2022 07; 67(7):3129-3137.
Score: 0.034